Medical Oncologist
Breast cancer targeted therapy
Targeted Therapy for Breast Cancer: — HER2, HR+ and Triple Negative
Breast cancer targeted therapy is not one treatment — it is a group of medicines matched to the specific biology of your tumour. Three test results on your biopsy tissue are what decide which approach applies to you.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Tests first, treatment second — Your HER2, hormone receptor and BRCA results determine which targeted therapy, if any, applies to your cancer.
- Three subtypes, three different pathways — HER2-positive, hormone receptor positive and triple-negative breast cancers each have a distinct targeted treatment approach.
- Testing uses your existing biopsy — Biomarker tests are usually done on the tissue from your diagnostic biopsy — a new procedure is rarely needed to establish eligibility.
- Not eligible is not a dead end — Being told a particular targeted treatment does not apply is information about your tumour biology, not a measure of how serious your situation is.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy for breast cancer targets specific proteins or gene changes on your tumour cells rather than all dividing cells. Which treatment your oncologist recommends depends on three test results: your HER2 status, your hormone receptor status, and in some cases your BRCA gene result.
Which tests decide what targeted therapy you will receive?
Three test results on your tumour tissue decide which targeted treatment, if any, is likely to work for you.
The first is HER2 status, tested by immunohistochemistry on your biopsy sample and confirmed by a gene test called FISH if the initial result is borderline.
The second is hormone receptor status — whether your tumour cells carry oestrogen or progesterone receptors.
Some patients are also tested for inherited BRCA1 or BRCA2 gene changes, which open a separate group of targeted options, particularly in advanced disease.
What targeted therapy is used for HER2-positive breast cancer?
HER2-positive breast cancer is treated with medicines that block the HER2 protein directly on the cancer cell surface.
NCCN and ESMO guidelines recommend anti-HER2 therapy as a core part of treatment for HER2-positive disease, whether the cancer is early-stage or advanced.
These medicines are given by intravenous infusion, usually as day care, alongside or after chemotherapy depending on the stage.
For early HER2-positive disease, a further defined period of anti-HER2 treatment after surgery aims to reduce the risk of the cancer returning.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What do these test results mean in plain language?
- HER2-positive
- The tumour has too many copies of the HER2 protein. This makes it sensitive to medicines that block that protein specifically.
- Hormone receptor positive (HR+)
- The tumour carries receptors for oestrogen, progesterone, or both. Medicines that reduce or block these hormones can slow its growth.
- Triple negative (TNBC)
- The tumour tests negative for HER2, oestrogen receptors and progesterone receptors. Standard hormone and anti-HER2 medicines do not work here; options depend on BRCA mutation status and PD-L1 expression.
- BRCA1 / BRCA2 mutation
- An inherited gene fault that, in some advanced breast cancers, makes the tumour sensitive to a class of medicines called PARP inhibitors.
- CDK4/6 inhibitor
- A targeted medicine used alongside hormone therapy in hormone receptor positive, HER2-negative advanced breast cancer. It blocks proteins that cancer cells need to copy themselves.
- Ki-67
- A marker that shows how fast tumour cells are dividing. It does not decide targeted therapy on its own but helps guide decisions about how intensive treatment needs to be.
What targeted therapy is used for hormone receptor positive breast cancer?
If your tumour is hormone receptor positive and HER2 negative, the main targeted approach involves medicines that reduce oestrogen levels in the body or block oestrogen from reaching the tumour.
For advanced or metastatic HR-positive, HER2-negative disease, NCCN and ESMO guidelines recommend adding a CDK4/6 inhibitor alongside hormone therapy in eligible patients.
This combination aims to delay disease progression compared with hormone therapy given alone.
Patients with a BRCA mutation and advanced HR-positive disease may also be eligible for PARP inhibitors at a later stage of treatment, depending on what prior therapy has been received.
What else should I know about breast cancer targeted therapy?
What targeted options exist for triple-negative breast cancer?
Triple-negative breast cancer does not respond to hormone therapy or anti-HER2 medicines. If you carry a BRCA1 or BRCA2 gene change, PARP inhibitors are a recognised option in advanced triple-negative disease, as noted in NCCN and ESMO guidance. If your tumour tests positive for PD-L1 expression, adding a checkpoint inhibitor to chemotherapy is recommended in some guidelines for advanced disease. An antibody-drug conjugate approach is also available in advanced triple-negative disease regardless of BRCA or PD-L1 status, per current NCCN guidance. Ask your oncologist which of these tests has been done and what the results showed.
How long does targeted therapy for breast cancer continue?
The length of treatment depends on your cancer subtype and stage. For early HER2-positive breast cancer, anti-HER2 therapy is typically given for a defined period after surgery, as set out in NCCN guidelines. For advanced hormone receptor positive disease, treatment usually continues for as long as it is working and you are tolerating it. Your oncologist will review your response at regular intervals using imaging and blood tests, and will adjust the plan based on those results.
What side effects should I expect from targeted therapy?
Side effects vary considerably between drug classes, so your experience will depend on which medicine you receive. Anti-HER2 medicines can affect heart function, so heart monitoring is done at regular intervals during treatment. CDK4/6 inhibitors commonly lower blood counts, which is why blood tests are repeated regularly. Hormone therapy is associated with joint pains, hot flushes and other menopausal symptoms. PARP inhibitors can cause fatigue, nausea and low blood counts. Tell your team about any new symptom at your next contact rather than waiting for a scheduled appointment.
Can targeted therapy be given at the same time as chemotherapy?
It depends on the drug. Anti-HER2 therapy is usually given alongside chemotherapy in HER2-positive breast cancer, whether chemotherapy is given before surgery or after. Hormone therapy, by contrast, is almost always started after chemotherapy has finished rather than at the same time. CDK4/6 inhibitors are combined with hormone therapy, not with chemotherapy. If you are unsure about the sequence of your medicines and why they are ordered the way they are, ask your oncologist to explain the schedule at your next appointment.
What happens if targeted therapy stops working?
Targeted therapy can become less effective over time as cancer cells develop resistance. When that happens, your oncologist will reassess your results — sometimes using a repeat biopsy, because a tumour can change its characteristics. The options available after a first targeted therapy depend on what you have already received, your current test results and your overall fitness. Being told the current treatment is no longer working does not mean all options are exhausted; it means the treatment plan moves to the next step.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is targeted therapy the same as chemotherapy for breast cancer?
No. Chemotherapy attacks all rapidly dividing cells throughout the body, which is why it causes hair loss and affects the gut. Targeted therapy acts on specific proteins or gene products found on cancer cells, leaving most normal cells unaffected. In practice, some treatments combine both: anti-HER2 therapy is often given alongside chemotherapy in HER2-positive disease, and chemotherapy remains central to triple-negative treatment. They are different tools that work differently, and in some situations are used together.
How do I find out if my breast cancer is HER2-positive?
HER2 status is determined by a test on your biopsy tissue, carried out by the pathology laboratory as part of the standard workup after diagnosis. The result is reported as HER2-positive, HER2-negative, or borderline — a borderline result is usually confirmed with a second test called FISH. You do not need to arrange this separately; it is a standard test done on the same tissue used to diagnose you. Ask your oncologist to confirm the result and explain what it means for your treatment.
Does triple-negative breast cancer have no targeted treatment at all?
Triple-negative breast cancer has fewer targeted options than HER2-positive or hormone receptor positive disease, but it is not without targeted approaches. BRCA mutation testing and PD-L1 testing on your tumour tissue open specific pathways: PARP inhibitors for BRCA-mutated advanced disease, and checkpoint inhibitor combinations for PD-L1-expressing tumours. An antibody-drug conjugate approach is also available in advanced triple-negative disease. Chemotherapy remains a central part of triple-negative treatment, and your oncologist will explain which combination applies to your results.
What is the goal of targeted therapy in breast cancer?
The goal depends on the stage of your cancer. In early breast cancer, targeted therapy aims to reduce the risk of the cancer returning after surgery. In advanced or metastatic breast cancer, the aim is to control disease for as long as possible, manage symptoms and maintain quality of life. Your oncologist will explain what your specific treatment is expected to achieve, because the answer differs between a patient treated after surgery and one whose cancer has spread.
Is targeted therapy for breast cancer available at CION?
Yes. Anti-HER2 infusions are given as day care at CION centres across the network. Oral targeted medicines such as CDK4/6 inhibitors and hormone therapy are prescribed and monitored through CION. Biomarker testing — including HER2 status, hormone receptor status and BRCA testing — is coordinated through pathology services. If a relevant test has not yet been arranged, ask your oncologist whether it needs to be done.
My BRCA result was negative. Does that mean no targeted therapy for triple-negative breast cancer?
A negative BRCA result does not remove all targeted options for triple-negative breast cancer. PD-L1 testing is the next relevant test: a positive result makes a checkpoint inhibitor combination a guideline-recommended approach in advanced disease, as noted by NCCN. An antibody-drug conjugate approach is also available in advanced triple-negative disease regardless of BRCA or PD-L1 status. Ask your oncologist which biomarker tests have been completed and which results are still pending, so you have a full picture of which options apply to you.